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ABSTRACT OF THE THESIS 
Retinoic Acid Regulation of Thyroid Hormone Action in Bone Cells   
by 
Anjali Babbar 
Master of Science, Graduate Program in Microbiology and Molecular Genetics 
Loma Linda University, March 2014 
Dr. Subburaman Mohan 
  
 Retinoic acid and thyroid hormone are known to play key roles in the regulation 
of endochondral ossification. However, the issue of whether these two hormones interact 
with each other to regulate bone functions remains to be established. We investigated 
how thyroid hormone and retinoic acid interact to regulate cells involved in endochondral 
bone formation. We demonstrate that thyroid hormone treatment stimulates 
differentiation of ATDC5 chondrocytes and promotes formation of mineralized nodules 
while retinoic acid treatment at high dose inhibits chondrocyte differentiation and 
formation of mineralized nodules. Furthermore, thyroid hormone induced mineralized 
nodule formation is inhibited by co-treatment with retinoic acid in ATDC5 cells. Dose 
response studies in ATDC5 cells showed that retinoic acid treatment caused a biphasic 
effect on ALP and osterix mRNA levels. At low dose, it increased expression levels and 
at high dose it decreased the expression levels of ALP and osterix genes. Since thyroid 
hormone action in the nucleus is known to be mediated via binding of thyroid hormone 
receptors either as homodimer or heterodimer with retinoic acid receptors to regulatory 
regions of target genes, our findings raise the possibility that the presence of retinoic acid 
may interfere with the differentiation promoting actions of thyroid hormone in 
chondrocytes by influencing nuclear proteins that are recruited to the thyroid hormone 
x 
receptor complex. In conclusion, our findings suggest that the effect of retinoic acid 
treatment appears to be complex involving both stimulation and inhibition of 
differentiation depending on dose as well as differentiation status of cells.       
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CHAPTER ONE 
INTRODUCTION 
 
 Bone is a dynamic organ which undergoes continuous remodeling throughout life. 
Bone remodeling is a process in which osteoblasts form new bone and osteoclasts resorb 
the bone. This process is essential for maintaining the required bone mass to provide 
mechanical support to the body. An increase in bone mass occurs during childhood and 
adolescence by the process of endochondral bone formation (1). Bone mass attains its 
maximum peak during adulthood, where there is a balance in the activity of osteoblasts 
and osteoclasts. In normal conditions, the bone mass is sustained by tight coupling 
between the osteoblasts and osteoclasts. Numerous factors like diet, exercise and 
endocrine hormones influence bone growth and development. Endocrine hormones 
regulate the communication between osteoblasts and osteoclasts (2). 
 
Ossification of Bone 
 The process of ossification involves two different mechanisms - intramembranous 
ossification and endochondral ossification. Intramembranous ossification is a process 
where bone cells are directly formed from mesenchymal cells. This type of ossification is 
responsible for the development of flat bones in the body like clavicle, scapula and bones 
of the skull. The other process of ossification which involves the development of long 
bones of the body is known as endochondral ossification. It is a mechanism which 
involves formation of a cartilaginous model through condensation of mesenchymal cells 
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which later is gradually replaced by bone. Endochondral ossification occurs at two 
different sites in long bones i.e. primary (diaphysis) and secondary (epiphysis) (3). Bone 
development starts at the primary center of ossification and the secondary center is 
ossified later. Between the two centers of ossification lies the epiphyseal cartilage which 
is responsible for the growth of long bones. The epiphyseal cartilage consists of various 
layers of chondrocytes. The basal layer which is away from the ossification front is the 
zone of resting chondrocytes. Adjacent to the basal layer is the zone of proliferation 
where rounded cells gradually become flattened as they pack into multicellular clusters. 
Following proliferation, chondrocytes pass through a transition stage of pre- hypertrophic 
chondrocytes where they undergo maturation and secrete extracellular matrix and then 
die. As the chondrocytes die, this region is invaded by blood vessels and macrophages 
which clear up the dying chondrocytes and precursors of osteoblasts start laying down the 
bone. 
 
Bone Cells 
 Osteoblasts are specialized mesenchymal cells which are responsible for bone 
formation. Depending on the signaling pathway, mesenchymal stem cells can 
differentiate into cells such as fibroblasts, chondrocytes, myoblasts or adipocytes (4). 
Once osteoblasts differentiate they undergo proliferation and then deposit extracellular 
matrix and bring about matrix maturation and mineralization. Expression levels of 
various differentiation markers such as alkaline phosphatase (ALP), collagen type1, 
osteopontin and osteocalcin are used to study osteoblast differentiation. RUNX2 acts as a 
main switch to initiate osteoblast differentiation and it regulates the expression level of 
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the above stated genes (5). Osterix which is downsteam of Runx2 is another key 
transcription factor for osteoblast development (6). 
 Chondrocytes are mesenchymal derived cells whose function is to produce the 
extracellular matrix of cartilage. This matrix includes aggrecans and type II collagen and 
other proteins. Chondrocytes are responsible for both appositional and interstitial growth 
of cartilage and are involved in endochondrial bone formation (7). In endochondral bone 
formation, differentiated chondrocytes within cartilage undergo controlled proliferation 
and hypertrophy. They form distinct zones along the longitudinal axis during the process 
of  bone elongation. Collagen type II is expressed by proliferating chondrocytes and 
hypertrophic chondrocytes express collagen X. Indian hedgehog is expressed by 
prehypertrophic chondrocytes and provides a signal to adjacent perichondrium to 
stimulate osteoblast differentiation (8).  
   
Regulators of Endochondral Ossification 
 The chondrocytes of the growth cartilage are under the influence of both systemic 
factors and local factors (9). The systemic factors include growth hormone, thyroid 
hormone (T3), glucocorticoids and vitamins. The local factors include insulin like growth 
factor, indian hedgehog, parathyroid hormone related peptide, bone morphogenic proteins 
and fibroblast growth factors. Among the various regulators of endochondral ossification, 
the present study concentrates on thyroid hormone and how it regulates endochondral 
ossification.  
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Thyroid Hormone 
 Bone development is dependent on coordinated actions of genetic, nutritional, 
endocrine and environmental factors. Thyroid hormone (T3) is considered essential for 
growth and development in children. Thyroid hormone is secreted by the thyroid gland 
under the control of thyroid stimulating hormone (TSH) released by the pituitary.  
Hypothyroidism is caused by a deficiency of thyroid hormone or by a mutation in the 
thyroid hormone receptor that can lead to growth arrest, a slowing of  bone formation or  
epiphyseal dysgenesis in children (10).Thyrotoxicosis, a condition that leads to 
hyperthyroidism in growing children, results in accelerated bone growth, premature 
closing of the growth plate and short stature. 
The actions of thyroid hormone are mediated by thyroid hormone nuclear 
receptors. The thyroid receptors act as hormone activated transcription factors which 
modulate gene expression (11). These receptors are expressed as TRα and TRβ; each of 
these exhibits in two isoforms- TRα1, TRα2, TRβ1, and TRβ2.  TRα and TRβ possess 
related T3 and DNA binding domains but separate amino terminals (12). Thyroid 
receptors are usually expressed in the reserve, proliferative and pre hypertrophic zones of 
the epiphyseal plate and in osteoblasts of primary spongiosum (13,14).  
Thyroid hormone receptors have an amino terminal domain, a central DNA 
binding domain and a carboxy terminal ligand binding domain. The DNA binding 
domain is present in the central part of thyroid hormone receptor which consists of two 
zinc fingers formed by four cysteine residues. Thyroid hormone receptors bind to a small 
segment of DNA known as the thyroid response element (TRE). The binding of thyroid 
hormone receptor to TRE can be in the form of homodimers, i.e., with the other thyroid 
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hormone receptor, or in the form of heterodimers with the retinoid X receptor (RXR). 
The heterodimers are known to increase the DNA binding and transcription process (15).  
The ligand binding domain binds to thyroid hormone and is also responsible for 
dimerization, transactivation and basal repression by ligand free thyroid hormone 
receptor. Thyroid hormone penetrates the nucleus where it binds to the thyroid hormone 
receptors which may already be bound to TRE located in the promoter regions of target 
genes. Ligand- bound thyroid hormone receptor complex which is bound to the TRE is 
crucial for the repression or activation of the target genes involved. Various 
cotransfection studies have revealed that unliganded thyroid hormone receptors can 
repress the transcription of positively regulated TREs (16, 17). In the ligand- free state, 
the transactivation domain of the T3 free receptor, heterodimerized with RXR, adopts a 
conformation that encourages the assembly of transcriptional corepressor factors. The 
formation of the corepressor complex has histone deacetylase activity which is associated 
with the formation of compact chromatin, which represses transcription of affected genes 
(18). On the contrary, in the ligand bound state, the binding of T3 to its receptor 
stimulates a conformational change in the receptor that makes it incapable of binding to 
the corepressor complex, but capable of binding to a group of coactivator proteins (19). 
The coactivator protein complex promotes histone transacetylase activity which exposes 
the chromatin and activates transcription of linked genes.   
 
Retinoic Acid 
 Retinoic acid (RA) is a fat soluble molecule which is synthesized from vitamin A. 
Retinoic acid is essential for vision, immune responses, bone growth, reproduction and 
hematopoiesis (20). Production of retinoic acid in the body does not happen at all stages 
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of development but instead follows a spatiotemporal pattern (21). Deficiency or excess of 
retinoic acid has been considered as teratogenic due to anteroposterior patterning defects 
(22). Retinoic acid enters the nucleus and functions as a ligand for two families of nuclear 
receptors that bind to DNA and regulate transcription. The receptors of retinoic acid are 
RAR (RARα, RARβ, RARɣ) and RAX (RAXα, RAXβ, RAXɣ). RAR receptors usually 
bind to all-trans retinoic acid, which is the most abundant form of retinoic acid in body, 
and RAX binds to 9-cis-retinoic acid (23). 9-cis-retinoic acid is normally undetectable in 
the body except when there is an excess of vitamin A (24).  Retinoic acid signaling is 
initiated by the binding of retinoic acid to the retinoic acid receptor RAXs, which forms a 
stable heterodimer with RARs, vitamin D receptor and thyroid hormone receptor. The 
complex formed by binding of RAX with the various receptors in turn binds to the 
retinoic acid response elements in the regulatory regions of target genes (22).  
Retinoic acid is known to both promote and inhibit endochondral ossification but 
how it modulates the thyroid hormone action in bone cells is not known (25, 26, 27, 28, 
29). The present study is therefore focused on understanding if and how thyroid hormone 
and retinoic acid interact to regulate cells involved in endochondral bone formation. 
 
Hypothesis 
 Retinoic acid modulates thyroid hormone effect in bone cells.          
 
Specific Aims 
1. To determine if retinoic acid influences thyroid hormone’s effect on differentiation of 
chondrocytes and osteoblasts. 
7 
2. To evaluate the effect of thyroid hormone and retinoic acid on transcription factors 
which are critical for chondrocyte and osteoblast differentiation. 
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CHAPTER TWO 
MATERIALS AND METHODS 
 
Cell Culture 
ATDC5 Cells 
 The ATDC5 cell line is a murine chondrogenic cell line which was obtained 
from Ardent, San Diego. This cell line is widely used to study chondrocyte growth and 
differentiation. ATDC5 cells were maintained in DMEM/F12 media containing 5% fetal 
bovine serum. The cells were kept at 37⁰ in a humidified atmosphere of 5% CO2 for the 
culture period.  
 
Primary cells 
  The primary chondrocyte cells were isolated from ribs of mice aged 3-7 days. The 
rib cages of mice were isolated and digested in collagenase for one hour in a shaker at 
37⁰ to separate and clean the ribs. The ribs were then washed with PBS and digested 
again with collagenase for four hours in a shaker to isolate chondrocytes. After 
incubation, the cells were filtered and cultured in ascorbic acid- free α-MEM with 10% 
fetal bovine serum. When cells were 70%-80% confluent they were passed and plated 
again for the experiments. The primary osteoblasts were isolated from calvariae of mice 
aged 3-7 days. The mice were decapitated and calvaria was isolated and cut into four 
pieces. The calvarial pieces were treated with digestion buffer (collagenase and 
hyaluronidase mixture) and kept in a shaker at 37⁰ for 15 minutes. After incubation, they 
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were washed with PBS and filtered in a strainer. The fragments of calvaria were collected 
from the strainer and again treated with digestion buffer in a shaker for one hour and then 
washed with PBS. Filtrate was centrifuged and cultured in ascorbic- acid free α-MEM 
with 10% fetal bovine serum. When cells were 70%-80% confluent they were passed and 
plated again for the experiments. 
 
In-Vitro Bone Formation Assay 
Alizarin Red Staining 
 ATDC5 cells were plated in six well plates to determine the degree of bone 
mineralization in culture. Initially the cells were grown in proliferating media until they 
are 80-90% confluent. The proliferating media constitutes DMEM/F12 media containing 
5% fetal bovine serum + penicillin streptomycin. When cells became 90% confluent, we 
shifted the cells to differentiation media. The control differentiation media contains 
DMEM/F12 + 5% fetal bovine serum + penicillin streptomycin  + β-glycerol phosphate 
(10μM) and the experimental differentiation media contains DMEM/F12 + 5% fetal 
bovine serum + penicillin streptomycin  + β-glycerol phosphate (10μM ) + ascorbic acid 
(50μg/ml). Cultured cells were treated with retinoic acid (100nM), thyroid hormone 
(10ng/ml) and a combination of retinoic acid and thyroid hormone for 25 days. Fresh 
differentiation medium was changed every three days. Cells were observed closely after 
20 days as a layer of cells might start to lift around the edges. At 25 days, the cells were 
washed with PBS after carefully removing the media and fixed with 100% methanol for 1 
hour. After fixing, the cells were stained with alizarin red stain and incubated at room 
temperature for 10 min. Alizarin red stain was removed and nodules were washed with 
de-ionized water and agitated slowly repeatedly until the background appeared clear and 
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nodules were obvious. The quantification of the nodules was done as percent of area 
stained by using Image J software. 
 
ALP Staining 
Alkaline phosphatase staining was performed on day 7 in ATDC5 cells treated 
with retinoic acid (100nM), thyroid hormone (10ng/ml) and their combination. The cells 
were washed with PBS and fixed in 100% methanol for 20 min at the 7th day of 
treatment. The methanol was removed and cells were stained in ALP staining solution 
(substrate-diazonium solution) and incubated for 30 min at 37⁰ incubator. ALP positive 
cells (red) were identified under the microscope. 
 
RNA Isolation and Gene Expression 
 RNA was extracted from the cells by Trizol, chloroform and RNeasy mini kit    
(Qiagen, Valencia, CA).The culture dishes were washed with PBS after removing the 
media. Trizol was added to the culture dish to lyse the cells and cell scrapper was used to 
remove the cell lysate from the dish plates. The cell lysate was collected in a micro-
centrifuge tube and chloroform was added to the cell lysate and incubated for 2-3 min. 
The cell lysate was centrifuged at 4⁰ for 15 min. Following centrifugation, the mixture 
separated into a lower pink phase, a chloroform layer, an interphase layer and a colorless 
upper aqueous layer. RNA located in the aqueous layer was carefully removed without 
disturbing the interphase and added to  a new tube. RNA was precipitated from the 
aqueous phase by adding 70% ethanol. The samples were vortexed and transferred to 
columns of the RNeasy mini kit. The samples were then washed with wash buffers I and 
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II. After washing the columns were transferred to RNA collecting tubes and  25 uL of 
DEPC water was added on the membrane of the column. Tubes were centrifuged for 1 
min and RNA was collected. RNA was quantified using NanoDrop spectrophotometer. 
 Reverse transcription was done using Superscript (Invitrogen, Carlsbad, CA), to produce 
cDNA. Quantitative real time PCR was performed to examine the expression of osterix, 
osteocalcin, ALP, RUNX2 and SOX9 genes. The PPIA gene was used as an internal 
control in PCR reaction. ∆CT values were obtained by subtracting CT value for control 
gene from CT value for the gene of interest.  
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CHAPTER THREE 
RESULTS 
 
Effect of TH and/or RA on Alkaline Phosphatase Staining in 
ATDC5 Chondrocytes 
Initially to estimate the level of chondrogenic differentiation, alkaline phosphatase 
staining was performed in ATDC5 cells on the seventh day of treatments with various 
factors. In vehicle treated control cells, a moderate level of alkaline phosphatase staining 
was observed. The intensity of staining was increased in cultures treated with TH (Fig. 
1a). The positive effect of TH on alkaline phosphatase staining was abolished by co-
treatment with retinoic acid (Fig. 1b).  
 
 
Fig. 1a. Alkaline phosphatase staining in ATDC5 cells treated with Control and TH for 7 
days. 
Control 
TH 
13 
 
Fig. 1b. Alkaline phosphatase staining in ATDC5 cells treated with RA and TH + RA for 
7 days. 
 
 
Effect of TH and/or RA on Formation of Mineralized Nodules in 
ATDC5 Cells 
In order to determine whether TH and/or RA influences mineralization in ATDC5 
chondrocytes, ATDC5 cells were treated with 10ng/ml of TH and/or 100nM of RA. 
Alizarin red staining of mineralized nodules after 25 days of treatment with TH and/or 
RA revealed that TH caused a significant increase in % of mineralized area (Fig 2a). On 
the contrary, RA decreased % mineralized area both in vehicle and TH treated cultures 
(Fig 2b).  
 
 
 
 
RA 
TH +RA 
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    Control                                   TH                          RA                  TH+RA 
Fig. 2a. Effect of TH and/ or RA on formation of mineralized nodules in ATDC5 cells. 
 
         
 
Fig. 2b. Quantitation of mineralized nodule area in ATDC5 cells treated with TH, RA, 
and TH+RA. 
   
 
Effect of TH and/or RA on Osteocalcin mRNA Levels 
To determine if TH and RA regulate the expression levels of osteocalcin, a key 
marker of differentiated osteoblasts, ATDC5 chondrocytes were treated with TH and/or 
RA. We observed a significant increase in the expression of osteocalcin mRNA by TH 
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hormone treatment. However, TH effect on osteocalcin expression was increased by 
treatment with RA (Fig. 3.)  
 
 
Fig. 3. Effect of TH and/ or RA on osteocalcin mRNA levels. 
 
 
Dose-dependent Effect of RA on TH-induced ALP mRNA  
 In order to investigate dose effect of RA on the TH induced increase in ALP 
mRNA levels, ATDC5 cells were plated and treated with different concentrations of  RA 
(0.01nM- 10nM) with and without TH (1ng/ml) for 24 hours. RA treatment caused a 
biphasic effect on ALP mRNA levels with an increase at low dose and a decrease at high 
dose (Fig. 4). The TH-induced increase in ALP mRNA was decreased by RA treatment in 
a dose dependent manner (Fig. 4).  
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Fig. 4. Dose response effect of RA and TH with RA on ALP mRNA levels in ATDC5 
cells. 
 
Dose-dependent Effect of Retinoic Acid on TH-induced Osterix 
mRNA Levels 
ATDC5 chondrocytes showed an increase of 2.2 fold in osterix expression upon 
treatment of RA at 0.01nM as compared to vehicle treatment (Fig 5). However, this 
increase in osterix expression by retinoic acid was not seen at high doses. TH treatment 
alone caused a significant increase in osterix mRNA level which was further increased by 
RA at low dose but not at high dose (Fig 5).  
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Fig. 5. Dose response effect of RA and TH with RA on osterix mRNA levels in ATDC5 
cells. 
 
Effect of TH and/or RA on Osterix, ALP, Osteocalcin and SOX9 
mRNA Levels in Primary Chondrocytes 
 
To determine if TH and/or retinoic acid produced similar effects on gene 
expression in primary chondrocytes, we evaluated the effects of these treatments using 
untransformed normal primary chondrocytes. TH caused a significant increase in osterix 
expression. However, RA treatment did not significantly change TH’s effect on osterix 
expression (Fig 6a). 
Both TH and RA caused similar increases in ALP mRNA levels. Their 
combination, however, resulted in greater induction than that observed with individual 
treatments (Fig 6b). 
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Treatment with TH or RA increased osteocalcin mRNA levels. RA did not 
significantly alter TH effects on osteocalcin mRNA levels (Fig 6c). SOX9 mRNA levels 
displayed an increased expression with TH treatment. However, RA alone and in 
combination with thyroid hormone treatment did not increase SOX9 expression levels 
(Fig 6d). 
 
 
  
 
Fig. 6a. Effect of TH and/ or RA on osterix mRNA levels in primary chondrocytes. 
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Fig. 6b. Effect of TH and/ or RA on ALP mRNA levels in primary chondrocytes. 
 
 
 
 
Fig. 6c. Effect of TH and/ or RA on osteocalcin mRNA levels in primary chondrocytes. 
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Fig. 6d. Effect of TH and/ or RA on SOX9 mRNA levels in primary chondrocytes. 
 
 
Effect of TH and/or RA in Osterix and ALP mRNA Levels in 
Primary Osteoblasts 
Untransformed primary osteoblasts derived from calvariae of 3 day old mice were 
cultured and treated with TH, RA and their combination for 24 hrs. Treatment with TH 
and RA caused an increase in osterix and ALP expression levels (Fig 7a and 7b). RA did 
not suppress the TH induced increase in osterix and ALP mRNA levels (Fig 7a and 7b)  
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Fig. 7a. Effect of TH and/ or RA on osterix mRNA levels in primary osteoblasts. 
 
 
 
 
Fig. 7b. Effect of TH and/ or RA on ALP mRNA levels in primary osteoblasts. 
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CHAPTER FOUR 
DISCUSSION 
 
Vitamin A is required to maintain healthy vision, teeth, strong immune system, 
cell growth and differentiation. It is usually an essential component found in multivitamin 
supplements, cod liver oil, eggs and fortified foods. Deficiency and excess of Vitamin A 
are known to cause profound effects on bones. Early studies to observe the function of 
Vitamin A on the developing skeleton demonstrated that it acts to control the location and 
activity of osteoblasts, thus determining the shape and texture of bones (30). The excess 
of Vitamin A has been implicated to produce bone fractures in both in vivo and in vitro 
studies (30, 31). Many studies have associated an excess of retinol with old age hip 
fractures, especially in postmenopausal women (32). This effect of hypervitaminosis A 
has been shown to increase the size and number of osteoclasts thus leading to bone 
resorption, deterioration of cartilage in rats and spontaneous fractures (33, 34). 
Our study indicates that treatment of thyroid hormone stimulates differentiation of 
ATDC5 chondrocytes and promotes formation of mineralized nodules. On the contrary, 
retinoic acid treatment decreased formation of the mineralized area both in vehicle and 
thyroid hormone treated cultures. Retinoic acid has been shown to exhibit a similar 
decrease in formation of mineralized nodule in periodontal ligament cells (35). Thus, 
retinoic acid at high dose blocks the thyroid hormone effects on cell differentiation.   
One of the key findings of this study is that the retinoic acid effect on chondrocyte 
differentiation is dose-dependent and biphasic. Dose response experiments showed that at 
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low doses, retinoic acid exerts anabolic actions by increasing the expression levels ALP 
and osterix genes. Accordingly, a previous study showed that low doses of retinoic acid 
increased expression levels of ALP, osteocalcin and osteopontin genes (28). Retinoic acid 
at high doses inhibited chondroycte differentiation as reflected by ALP staining as well as 
expression levels of chondrocyte differentiation markers.  Consistent with our findings, 
retinoic acid at high doses caused inhibition of longitudinal bone growth by causing 
premature epiphyseal closure (25, 26). 
Thyroid hormone treatment induces increases in ALP, osterix and osteocalcin 
mRNA levels of ATDC5 cells, primary chondrocytes and primary osteoblasts cells. Our 
findings on the positive effects of thyroid hormone in bone cells are consistent with 
published reports demonstrating increased ALP activity and osteocalcin mRNA levels in 
thyroid hormone treated cultures (36, 37). Our study also disclosed that the treatment of 
retinoic acid at high dose inhibited thyroid hormone effects in ATDC5 cells. There was a 
significant decrease in the expression of mRNA levels of ALP, osterix osteocalcin genes 
when thyroid hormone treatment was given along with retinoic acid at high dose. In 
terms of potential explanation for retinoic acid modulation of thyroid hormone action, it 
is known that thyroid hormone receptors interact with retinoic acid receptors to form 
heterodimers at the thyroid hormone response element of target genes.  Thus, retinoic 
acid binding to retinoic acid receptor might alter the interaction of retinoic acid receptor 
with thyroid hormone receptor and thereby influence the type of nuclear proteins 
recruited to the transcription complex of target genes such ALP, osterix and osteocalcin 
genes.        
24 
Surprisingly, retinoic acid treatment did not block the thyroid hormone effect on 
expression levels of ALP, osteocalcin and osterix in primary cultures of chondrocytes.  
Similarly, the differentiation promoting effects of thyroid hormone were not inhibited by 
retinoic acid in primary cultures of osteoblasts.  One can offer a number of potential 
explanations for the observed differences in retinoic acid action in ATDC5 versus 
primary chondrocytes.  In this regard, it is known that the actions of hormones and 
growth factors on target cells are dependent on stage of differentiation. Thus, the effect of 
retinoic acid on thyroid hormone action may be specific for a certain stage of 
development in bone cells, and primary chondrocytes and ATDC5 cells represent 
different stages in the chondrocyte differentiation pathway.  Another possibility is that 
the nature of thyroid hormone and retinoic acid receptors expressed in the two cell types 
may be different.  In any case, our findings are consistent with the known in vivo actions 
of retinoic acid that have been shown to vary depending on developmental stage, 
concentration and time (38, 39, 40). 
Another explanation for the dissimilarity in the behavior of ATDC5 cells and 
primary cells might be the origin of these two cells types. ATDC5 cells are pure 
chondrocytes whereas primary osteoblasts and chondrocytes are derived from the ribs of 
mice. The cells from different origins and isolation methods have their own 
characteristics. ATDC5 cells represent more cell homogeneity whereas the primary 
cultures contain connective tissue, fibroblasts and adipocytes, thus suggesting that these 
other cell types may influence retinoic acid’s effects on bone cells.  
Our findings cast a new light on the effect of retinoic acid on thyroid hormone 
action in bone cells. Our study demonstrated that retinoic acid treatment inhibits the 
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function of thyroid hormone by reducing mineralized nodule formation and suppressing 
the expression of ALP, osterix and osteocalcin genes. Our observation in the present 
study raises some questions regarding how the retinoic acid is interfering with the 
coactivators at the thyroid response element complex of ALP, osterix and osteocalcin 
genes. To evaluate the effect of retinoic acid on thyroid hormone action, future studies 
should examine the molecular pathway by which retinoic acid might interfere with 
recruitment of co-activators at the thyroid response element complex. Organ culture 
experiments using long limbs of mice/rat can be performed with thyroid hormone and/or 
retinoic acid treatments to study how retinoic acid influences chondrocyte differentiation 
and endochondral bone formation. In- vivo studies in mice involving administrating 
thyroid hormone with increasing doses of retinoic acid can provide us with answers as to 
how retinoic acid regulates thyroid hormone’s effect on endochondral ossification.  
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